Tina J. Hieken

Mayo Clinic — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

42h-index7.2kcitations411works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(121), Cutaneous Melanoma Detection and Management(116), Breast Lesions and Carcinomas(68), CAR-T cell therapy research(60), Cancer Immunotherapy and Biomarkers(55)

Publications408 total

RP-1 Fires Up Tumors but Fails to Get FDA Approval
Annals of Surgical Oncology·2026Open Access
Biomarker analysis of circulating tumor DNA in clinical stage III melanoma patients treated with neoadjuvant immunotherapy combined with targeted therapy
Therapeutic Advances in Medical Oncology·2026Open Access
Comparison of partial breast radiation modalities in women with early-stage breast cancer: a target trial emulation
JNCI Journal of the National Cancer Institute·2025
A clinicopathologic and gene expression profile test improves predictive accuracy of sentinel lymph node status over established nomograms for cutaneous melanoma
European Journal of Surgical Oncology·2025
Supplementary Figure S1 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
2025Open Access
Supplementary Table S2 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Table S5 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Table S4 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
2025Open Access
Supplementary Table S3 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Table S1 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
2025Open Access
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases
UNC Libraries·2025Open Access
Clinical Stage II Melanoma: Is There a “Simple Trick” to Significantly Improve Event-Free Survival?
Annals of Surgical Oncology·2025Open Access
Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status
JAMA Surgery·2025· 4 citedOpen Access
Primary Merkel Cell Carcinoma of the Deep Breast Parenchyma
International Journal of Surgical Pathology·2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma
Annals of Surgical Oncology·2025· 1 citedOpen Access
Does RECIST 1.1 Predict Nodal Response to Neoadjuvant Chemo‐Immunotherapy in Breast Cancer?
Journal of Surgical Oncology·2025
ASO Visual Abstract: Accuracy of PET–CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment
Annals of Surgical Oncology·2025
page 1 of 21Next →

Frequent Co-authors

Judy C. Boughey(16), Amy C. Degnim(13), James W. Jakub(13), Tanya L. Hoskin(9), Elizabeth B. Habermann(6), Daniel W. Visscher(6), Karthik Ghosh(5), Tapas K. Das Gupta(4), Derek C. Radisky(4), Josè M. Velasco(4), Svetomir N. Markovic(4), Katrina N. Glazebrook(4), Charlotte E. Ariyan(3), Vernon K. Sondak(3), John F. Thompson(3), Alexander C. J. van Akkooi(3), Hussein A. Tawbi(3), Matthew S. Block(3), David Gyorki(3), Michael Lowe(3)